Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 11/20 | 0.50 |
| ▸ | F10 | P00742 | 2/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.45 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3278076 | 0.92 | F2 (0.55) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL3277603 | 0.90 | SMPD1 (0.48) | SMPD1 | |
| SCHEMBL3279407 | 0.86 | F2 (0.54) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL3278168 | 0.83 | F2 (0.60) | F2F10 | |
| SCHEMBL3284334 | 0.80 | MAOB (0.48) | — | |
| SCHEMBL3281929 | 0.77 | F2 (0.58) | F2F10 | |
| SCHEMBL7071599 | 0.74 | MAP4K4 (0.45) | F2F10 | |
| SCHEMBL3278218 | 0.73 | LOXL2 (0.43) | F2SMPD1 | |
| SCHEMBL23902232 | 0.70 | PRSS1 (0.79) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL7071621 | 0.70 | GRM5 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1907368-A1 | 2-CYANO-PYRIMIDINES AND -TRIAZINES AS CYSTEINE PROTEASE INHIBITORS | Novartis AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007009715-A1 | 2-CYANO-PYRIMIDINES AND -TRIAZINES AS CYSTEINE PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | disclosed |